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Abstract 
Purpose: To explore the therapeutic effect and mechanism of action of Si–jun–zi decoction (SJZD) in 
rat spleen deficiency syndrome. 
Methods: Spleen deficiency syndrome was induced in a rat model with reserpine. Liquid 
chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS) and partial least squares-
discriminate models (PLS-DA) were used to analyze the difference in global metabolite profile within all 
groups. Variable importance projection (VIP > 1) and Student’s t–test (p < 0.05) were used for 
biomarker selection. 
Results: Enzymatic results showed that the level of amylase (AMY), pepsin (LPS) and pepsase were 
significantly lower in the untreated rats than in normal control rats and SJZD group rats (P < 0.05). 
Histopathological analysis showed there were significant pathological changes in the untreated rats 
compared with the normal control group and SJZD group rats. PLS-DA score plots of the untreated 
group rats clustered separately from control rats, whereas SJZD group rats clustered closely to normal 
control rats. Twenty potential biomarkers, including phospholipid and fatty acids, were screened. The 
relative content of 20 metabolites showed significant differences in the untreated group compared with 
control and SJZD groups (p < 0.05). Six potentially perturbed metabolic pathways were found, which 
might be potential targets pathways for SJZD intervention in spleen deficiency syndrome. 
Conclusion: Metabolomics approach is an effective tool for understanding the therapeutic mechanisms 
of SJZD.  
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Spleen deficiency syndrome is a common 
disease syndrome treated in traditional Chinese 
medicine (TCM) practice that causes patients to 
suffer from poor health and fatigue. It comprises 
a comprehensive set of pathological changes 
that reduce the function of multiple organs and 
systems based on the abating function of 
digestion and nutrient absorption [1]. Si–jun–zi 
decoction (SJZD), a classic traditional Chinese 
medicine, has been proved to have positive 
effects on spleen deficiency syndrome. However, 
there are very few reports dealing with the 
therapeutic mechanisms of SJZD on spleen 
deficiency syndrome using a modern scientific 
strategy. 
 
Metabolomics, an emerging field of systems 
biology, is a strong analytical tool because of its 
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high-throughput quantification ability for 
monitoring the levels of multiple endogenous 
metabolites, closely related to physiological and 
pathological processes [2]. Changes in levels of 
endogenous metabolites provide important 
information that can be used for early diagnosis, 
for studies on pathogenesis, for studies on 
potential therapeutic targets [3], and for the 
evaluation of the therapeutic and toxic effects of 
drugs [2].Currently, liquid chromatography mass 
spectrometry (LC-MS) technology has been used 
as an important tool in metabolomics research 
due to its high resolution, high sensitivity, and a 
wide range of mass [4]. 
 
In the study, a metabolomics approach based on 
LC-Q-TOF/MS with pattern recognition was used 
to identify changes in the levels of different 
metabolites in plasma samples from rats with 
spleen deficiency syndrome. A statistical analysis 
approach was applied to discover potential 
biomarkers and uncover the key pathways that 






Micro-imaging system (Olympus, Tokyo, Japan).  
An Agilent 1290 Infinity LC system coupled to an 
Agilent 6538 UHD Q-TOF/MS (Agilent 
Corporation, USA). An Acquity LC HSS T3 
column (2.1×100 mm, 1.8 µm, UK).  
 
Chemicals and reagents 
 
HPLC grade acetonitrile was purchased from 
Merck (Darmstadt, Germany). Reserpine 
injection (batch No. 1411291) was from 
Guangdong Bangmin Pharmaceutical Co., Ltd. 
(Jiangmen, PR China). Atropine sulfate (2mL: 1 
mg, batch no. 140338005B) and physiological 
saline (batch no. WF111109) were from Anyang 
jiuzhou Pharmaceutical Co., Ltd. (Anyang, 
Henan, PR China). Codonopsispilosula (Franch.) 
Nannf. (Batch No. 401004713), 
Atractylodesnmacrocephala (batch No. 
002010401), Poriacocos (Schw.) wolf (batch No. 
002010301), and GlycyrrhizauralensisFisch 
(batch No. 003030601) were provided by 
Tongrentang of Beijing. SJZD composed of 
Codonopsispilosula (Franch.) Nannf, 
Atractylodesmacrocephala, Poriacocos (Schw.) 
Wolf, and GlycyrrhizauralensisFisch at a ratio of 
2:2:2:1 through water decoction for two times, 
then the decoction was concentrated (equivalent 
of crude drug concentration of 2 g/mL). AMY, 
LPS and lipase assay kits were obtained from 
Nanjing Jiancheng Bioengineering Institute 
(Nanjing, PR China). 
Spleen deficiency syndrome model and drug 
administration 
 
All procedures that involved animals were 
conducted in accordance with the National 
Institute of Health Guide for the Care and Use of 
Laboratory Animals [5]. All animal experiments 
were approved by Ethics Committee of Xinxiang 
Medical University (ref no. LLZM2014528). Forty 
male Sprague-Dawley rats (180 – 220 g); (rodent 
license no. SCXK 20100002) were supplied by 
Laboratory Animal Center of Henan Province 
(Zhengzhou, PR China).  
 
After acclimatization, the rats were randomly 
divided into four groups: normal control group 
(NC) (n = 10), the spleen deficiency syndrome 
model group (M) (n = 10), model rats treated with 
SJZD group (SJZD) (n = 10) and the model rats 
treated with atropine sulfate injection group (PC) 
(n = 10). Rats in the M, SJZD and PC groups 
were subcutaneously injected with 0.5 mL 
reserpine injection (0.1 mg/mL) in subcutaneous 
injection, while the NC group were injected an 
equivalent volume of 0.9 % saline once a day. 
Then the rats in SJZD group were given SJZD 
via gavage once a day (20 g/kg/d). The rats in 
PC groups were injected with atropine sulfate 
using subcutaneous injection mothed (0.5 
mg/kg/d); the NC group was injected equal 
volume of 0.9% saline once a day. All rats were 
continually treated for 14 days. 
 
Sample collection and pretreatment 
 
After 14 days, forty rats were anesthetized with 
10 % chloral hydrate following an overnight fast 
and two aliquots blood samples from the 
abdominal aortic were collected in heparinized 
and non-heparinized tubes, respectively. The 
whole blood of one aliquot in non-heparinized 
tubes was centrifuged at 3000 g for 10 min at 4 
°C to get the serum sample. The serum 
supernatant was immediately subjected for 
determination of AMY, LPS and pepsase activity 
using the assay kits. Another aliquot of the blood 
sample collected in heparinized tubes was 
centrifuged at 3000 g for 10 min at 4 °C to get 
the plasma samples.  
 
The plasma samples were immediately stored at 
-80 °C until metabolomic analysis. At the same 
time, stomach samples were fixed with 10 % 
poly-formaldehyde, embedded in paraffin, 
sectioned, stained with hematoxylin-eosin, and 
analyzed microscopically at 100× magnification 
for histopathological observation. Plasma sample 
for LC-Q-TOF/MS analysis was prepared by 
protein precipitation with ice-cold acetonitrile. 
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Acetonitrile (A) and water (B) were used as the 
mobile phases, with a gradient elution of 95 % B 
0 – 10 min, 80 % B at 10 – 15 min, 50 % B at 15 
– 23 min, 5 % B and 23 – 35 min. The flow rate 
and the injection volume were 0.25 mL/min and 
5µL, respectively. 
 
Mass spectroscopy was performed using a full 
scan mode from m/z 50 to 1200 for 35 min 
(positive and negative modes). The following MS 
analytical parameters were employed: nebulizer 
pressure, 45 psig; capillary voltage, 3.5 kV; 
drying gas flow of 11 L/min; fragmentor voltage 
120 V and gas temperature of 350 °C. 
 
Ten pooled quality control samples were injected 
before the analysis of two ion modes. The pooled 
quality control samples were injected at intervals 
of five samples during the whole experiment to 
further ensure the repeatability and stability of 
the analysis. 
 
Potential biomarkers and metabolic pathway 
analysis 
 
PLS-DA analysis and statistical analysis method 
were used to extract potential biomarkers based 
on the variable importance in the projection (VIP 
value >1) and Student’s t-test (p value < 0.05) 
between NC and M group. The selected potential 
biomarkers were identified by comparing 
databases according to the accurate molecular 
masses. Databases of KEGG (http://www. 
genome.jp/kegg/), MassBank (http://www. 
massbank.jp/), LIPID MAPS (http:// 
www.lipidmaps.org/) and HMDB 
(http://www.hmdb.ca) were used in the study. 
MetaboAnalyst 3.0 
(http://www.metaboanalyst.ca) was used to 




The raw LC-Q-TOF/MS data were transformed 
by MS Convert software, and R software was 
used for peak detection, deconvolution and 
alignment. The data were transformed into a 
single matrix containing with the retention time-
m/z pairs, normalized ion intensities and sample 
names, and then statistical analysis were 
performed through SIMCA-P+ software (version 
11.0; Umetrics AB, Umea, Sweden) and SPSS 
software (version 13.0; Beijing Stats Data Mining 





Enzyme activity  
 
AMY was assayed based on iodine - starch 
colorimetric method and LPS and pepsase were 
assayed based on colorimetric method. As 
shown in Figure 1, the levels of AMY, LPS and 
pepsase were significantly lower in model rats 
with spleen deficiency syndrome than in normal 
control rats (p<0.05). Rats in the PC group (rats 
treated with atropine sulfate) and SJZD group 
(model rats treated with SJZD), had higher levels 
of AMY, LPS and pepsase than model rats 
(p<0.05). There was no significant change in the 
levels of AMY, LPS and pepsase between rats in 
the PC group and SJZD group (p > 0.05), or 
normal control rats. These results revealed that 
SJZD treatment in rats with spleen deficiency 




Figure 1: Serum amylase, serum lipase and pepsase 
content in blood of rats in each group (Data was 
expressed as mean ± SD. Compared with NC group; 
△p > 0.05, *p < 0.05) 
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In comparison with control rats, rats with spleen 
deficiency syndrome exhibited numerous 
pathological changes in the tissues. These 
changes included disordered arrangement of 
gastric mucosal glands, obscure structures, 
partial gland atrophy, inflammatory exudate, 
slight hyperemia and edema in the interstitial 
tissue, and increased gastric epithelial cell 
mucus secretion (as shown in figure with the 
arrow). Histological features of the stomach 
tissues of the SJZD group rats, and the PC group 
rats were normal, similar to the tissues of the NC 
group rats (Figure 2). 
 
Repeatability and stability of LC-Q-TOF/MS 
analysis method 
 
Quality control analysis was carried out to assess 
the repeatability and stability of the LC-Q-
TOF/MS analysis method, using a pooled quality 
control sample injected at intervals of five 
samples (n = 5). The relative standard deviation 
of retention time was in the range of 0.05 – 0.15 
% for the positive ion mode, and 0.02 – 0.11 % 
for the negative ion mode. The relative standard 
deviation of the peak intensity varied between 
1.38 and 4.48 % for the positive ion mode, and 
between 1.75 and 6.53 % for the negative ion 
mode. These results show that our LC-Q-
TOF/MS analysis method had excellent 
repeatability and reliability. 
 
LC-Q-TOF/MS results for metabolic profiling 
 
The plasma samples of the experimental rats 
were analyzed by LC-Q-TOF/MS in both positive 
and negative ion modes. PLS-DA method was 
used with the LC-Q-TOF/MS data to reveal 
alterations of the basal metabolite profile 
between different groups. The results of PLS-DA 
analysis and the corresponding score plots (both 
in positive ion and negative ion modes) are 
shown in Figure 3. Plasma samples from 
untreated rats with spleen deficiency syndrome 
were clearly separated from control rats in the 
score plots. This shows that the normal plasma 
metabolic profile was remarkably disturbed due 
to the spleen deficiency syndrome. Plasma 
samples from untreated rats treated with SJZD, 
and from rats in the positive control group, 
clustered together with those of control rats, 
indicating that both drugs had a positive 
influence on spleen deficiency syndrome. These 
data also indicated that SJZD has a therapeutic 
effects, in agreement with histopathological and 
enzyme activity observations. 
 
Identification of metabolites 
 
Important compounds and metabolic pathways 
related to spleen deficiency syndrome were 
studies by plasma metabolic profiling. Metabolite 
differences between normal rats and rats with 
spleen deficiency syndrome were analyzed using 
PLS-DA technique (Figure 4). Values of the 
parameter R2Y of positive ion mode and negative 
ion modes were 0.993 and 0.998, respectively. 
This indicates that the technique for analysis 
could differentiate metabolites from untreated 
rats and those control rats. The values of the 
parameter Q2 in the positive ion mode and the 
negative ion mode were 0.989 and 0.997, 
respectively. This indicates that our technique for 




Figure 2: Histopathology features of the stomach by light microscopy in every group rats after 14 days.  (A-D): 
(A) normal control group rats; (B) M group rats; (C) SJZD group rats and (D) PC group rats 
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Figure 3: Scores plot from PLS-DA in positive and negative mode based on the LC-Q-TOF/MS data of rat 
plasma (A: positive ion mode B: negative ion mode. Modelling Diagnostic: A: R2X= 0.907, R2Y=0.934, Q2= 0.8. B: 
R2X= 0.927, R2Y=0.971, Q2= 0.934) 
 
 
Figure 4: Scores plot from PLS-DA based on the LC-Q-TOF/MS data of rat plasma (A: positive ion 
mode; B: negative ion mode). 
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A VIP value was obtained for each metabolite 
identified and ranked by its individual contribution 
to the statistical discrimination [6]. Based on 
comparison of the PLS-DA metabolic profiles 
between the model rats and control rats, on the 
VIP > 1.0, and on the p < 0.05 (estimated by 
Student’s t–test). Twenty potential biomarkers 
(six in the negative ion mode and ten in the 
positive ion mode) were screened. These 
metabolites are listed in Table 1(a) and Table 
1(b). Table 1 shows thirteen metabolites with 
decreased levels in model rats (relative to control 
rats), and seven metabolites with increased 
levels in untreated rats (relative to control rats). 
 
 
Metabolic pathway analysis of potential 
biomarkers 
 
Further analysis of the pathways affected in the 
rats with spleen deficiency syndrome was 
performed with MetaboAnalyst. The 21 potential 
biomarkers were imported to MetaboAnalyst, and 
the pathways potential biomarkers concerned 
were presented. As shown in Figure 5, the 
pathways where the impact value was greater 
than 0.1 were considered as potential target 
pathways. At last, six pathways were selected. 
They were as follows: alpha-linolenic acid 
metabolism, glycerophospholipid metabolism, 
fatty acid elongation in mitochondria, ether lipid 
metabolism; fatty acid metabolism, pyruvate 
metabolism. 
 
Table 1(a): Metabolites selected between the normal control group and the untreated group (negative ion mode) 
 
VIP tR(s) Mass 
 (m/z) 









1.04 1194.01 509.5755 ESI- LysoPC(O-18:0) ↑** ↑## Ether lipid metabolism 
1.03 1162.46 278.2724 ESI- a-Linolenic acid ↓** ↓## Fatty acid metabolism 
1.01 1472.94 809.6888 ESI- PC(16:0/22:4(7Z,10Z,13Z,16Z)) ↓* ↓
## Glycerophospholipid metabolism 
1.01 1471.26 809.5708 ESI- Acetyl-CoA ↓** ↓## Fatty acid metabolism 
1.01 960.11 889.4694 ESI- 6-Oxocyclohex-1-ene-1-carboxyl-CoA ↑** ↑
## Benzoate degradation 
 
Table 1(b): Metabolites selected between the normal control group and the untreated group (positive ion mode) 
 
VIP tR(s) Mass 
 (m/z) 





1.56 987.43 455.5195 ESI+ 20-Hydroxy-leukotriene E4 ↓** ↓# Arachidonic acid metabolism 
1.53 1417.90 771.4859 ESI+ PE(22:2(13Z,16Z)/16:0) ↑** ↑## Glycerophospholipid metabolism 
1.43 1497.10 354.4526 ESI+ Trioxilin A3 ↓** ↓# Arachidonic acid metabolism 
1.42 986.74 470.0892 ESI+ Glycerol 3-phosphate ↓** ↓## Glycerolipid metabolism 
1.35 1470.67 854.5724 ESI+ PC(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z)) ↓** ↓
## Glycerophospholipid metabolism 
1.21 1148.39 438.2395 ESI+ LPA(0:0/18:0) ↓* ↓# Fat digestion and absorption 
1.09 1133.17 428.2263 ESI+ Cholesteryl acetate ↓** ↓## Steroid biosynthesis 
1.08 1137.62 815.3956 ESI+ 3',4'-Anhydrovinblastine ↓* ↓## Indole alkaloid biosynthesis 
1.07 1305.90 118.1529 ESI+ Methylmalonic acid ↓** ↓## Valine, leucine and isoleucine degradation 
1.07 1354.13 256.3502 ESI+ Palmitic acid ↑** ↑# Fatty acid metabolism 
1.05 1470.36 730.6392 ESI+ SM(d18:1/18:0) ↑** ↑## Sphingolipid metabolism 
1.03 1474.61 811.4866 ESI+ PC(18:0/20:3(5Z,8Z,11Z)) ↑** ↑## Glycerophospholipid metabolism 
1.02 1456.45 705.6523 ESI+ CE(22:2(13Z,16Z)) ↑** ↑## Steroid biosynthesis 
1.01 1368.85 545.5390 ESI+ LysoPC(20:3(5Z,8Z,11Z)) ↓** ↓## Choline metabolism in cancer 
“↓”and “↑” represent the metabolite is down- and up- regulated in the model group compared with the normal 
control group, respectively. *p<0.05, **p<0.01, M vs NC. #p<0.05, ##p<0.01,M vs SJZD 
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Figure 5: Summary of pathway analysis with MetPA. 
Note: A: alpha-Linolenic acid metabolism; B: 
Glycerophospholipid metabolism; C: Fatty acid 
elongation in mitochondria; D: Ether lipid metabolism; 




SJZD is a famous traditional Chinese medicine 
that has gained general attention in recent years 
due to its extensive distribution and potential 
biological functions. In this study, the analysis of 
serum enzyme activities and his top athological 
analysis revealed protective effects of SJZD. 
These results were consistent with the results of 
our metabolomics analysis. Our findings clearly 
indicate that SJZD improved the condition of rats 
with spleen deficiency syndrome. 
 
The metabolomics analysis conducted in this 
study revealed that phospholipid and fatty acids 
could be potential biomarkers for spleen 
deficiency syndrome. Specifically, abnormalities 
in phospholipid metabolism are important causes 
of pathogenesis in spleen deficiency syndrome. 
The pathophysiological role of sphingolipids has 
also gained great attention. Phospholipids are 
important structural components of biological 
membranes, and it is largely divided into two 
categories: phosphoglyceride and 
sphingomyelin. Phosphoglyceride can be divided 
into different categories according to different 
functional groups, such as phosphatidylcholine, 
sphingomyelin, or phosphatidylethanolamine. 
Glucosylceramide, phosphatidylcholine 
(16:0/22:4(7Z,10Z,13Z,16Z)), lysophosphatidyl-
choline (O-18:0), phosphatidylethanolamine 
(22:2(13Z,16Z)/16:0), phosphatidylcholine 
20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z)), sphin-
gomyelin (d18:1/18:0), phosphatidylcholine 
(18:0/20:3(5Z,8Z,11Z)), all belong to the 
sphingolipid family. Lysophosphatidylcholines, 
also called lysolecithins, are formed through 
phosphatidylcholine hydrolysis by the enzyme 
phospholipase A2, and are a class of 
phospholipids derived from phosphatidylcholines 
[7]. Lysophosphatidylcholines activates protein 
kinase C and make vascular smooth muscles 
contract through Ca2+-dependent or Ca2+-non-
insulin dependent pathways. At the same time, 
inhibition of endothelium-derived nitric oxide, or 
the release or inactivation of endothelial 
hyperpolarization factor influences endothelial-
dependent relaxing, leading to endothelial-
dependent muscle contraction [8]. In this study, 
lysophosphatidylcholine (O–18:0) was up-
regulated in rats with spleen deficiency 
syndrome, relative to control rats. This result is 
consistent with the analysis of Shi et al. [9], 
which considered that an increased level of 
plasma lysophosphatidylcholines was a marker 
of cell membrane injury. Previous studies 
showed that lysophosphatidylcholine increases in 
response to reactive oxygen species and 
inflammatory conditions [10]. According to the 
saturation and the length of their acyl chains, 
lysophosphatidylcholine species exhibit 
differential abilities to induce the expression of 
cyclooxygenase-2 and prostaglandin [11]. 
Therefore, the increase of 
lysophosphatidylcholines (O–18:0) increase 
prostaglandin E2 levels in the plasma of rats with 
spleen deficiency syndrome. However, the 
relationship between plasma levels of 
lysophosphatidylcholines and spleen deficiency 
syndrome are not known, which will be the 
subject of more in-depth study. 
 
It has been reported that excessive free fatty 
acids may result in increased production of 
reactive nitrogen species and of reactive oxygen 
species, and subsequent oxidative stress [12]. In 
this study, the contents of free fatty acids in the 
plasma of rats with spleen deficiency syndrome 
were higher than those of normal control rats, 
rats in the positive control group, or model rats 
treated with SJZD. These higher values may be 
due to enhanced lipid metabolism (especially ω-
oxidation) and to a reduction in the 
corresponding circulating lipid levels [13]. The 
restoration of proper free fatty acids levels could 
be one of substance basis of the regulatory and 
therapeutic role of SJZD. 
 
Alpha-linolenic acid is a member of the group of 
ω-3 fatty acids. It cannot be synthesized in the 
mammalian body, and must be provided in the 
diet. Alpha-linolenic acid and otherω-3 fatty acids 
regulate the expression of a number of genes, 
including those involved in fatty acid metabolism 
and in inflammation. Alpha-linolenic acid is 
usually oxidized by many factors, including free 
radicals [14]. In this study, excessive free 
radicals induced by spleen deficiency syndrome 
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stimulated alpha-linolenic acid oxidation, 
resulting in decreased plasma levels of alpha-
linolenic acid in rats with spleen deficiency 
syndrome. SJZD exhibited antioxidant activity 
and inhibited alpha-linolenic acid oxidation, thus 
increasing alpha-linolenic acid levels in model 
rats treated with SJZD, relative to model rats with 
spleen deficiency syndrome. 
 
From the analysis of the plasma endogenous 
metabolites and the related metabolic pathways 
using an online metabolic network analysis tool. 
We speculate that alpha-linolenic acid 
metabolism, glycerophospholipid metabolism, 
fatty acid elongation in mitochondria, ether lipid 
metabolism, fatty acid metabolism, pyruvate 
metabolism were related to spleen deficiency 
syndrome. The six pathways were disturbed in 
the rats with spleen deficiency syndrome 
because of the level changes of the related 
potential biomarkers. These disturbed pathways 
were partly recovered towards healthy state in 
the SJZD group rats via SJZD treated on spleen 
deficiency syndrome rats. Therefore, we 
speculate that the six metabolic pathways may 
be the potential target of SJZD treatment spleen 




In this paper, both pharmacological (serum 
enzyme activity and histopathological 
observations) and metabolomics results 
indicated the good effect of SJZD on spleen 
deficiency syndrome rats. Six potential target 
metabolic pathways of SJZD treatment spleen 
deficiency syndrome rats were screened. 
Metabolomics approach may be an effective tool 
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